Bone Biologics Corp. (BBLG)
NASDAQ:BBLG
US Market
Holding BBLG?
Track your performance easily

Bone Biologics (BBLG) Stock Price & Analysis

60 Followers

BBLG Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.19%0.39%0.02%99.40%
0.19%
Insiders
0.02% Other Institutional Investors
99.40% Public Companies and
Individual Investors

BBLG FAQ

What was Bone Biologics Corp.’s price range in the past 12 months?
Bone Biologics Corp. lowest stock price was $0.80 and its highest was $10.56 in the past 12 months.
    What is Bone Biologics Corp.’s market cap?
    Currently, no data Available
    When is Bone Biologics Corp.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Bone Biologics Corp.’s earnings last quarter?
    Currently, no data Available
    Is Bone Biologics Corp. overvalued?
    According to Wall Street analysts Bone Biologics Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Bone Biologics Corp. pay dividends?
      Bone Biologics Corp. does not currently pay dividends.
      What is Bone Biologics Corp.’s EPS estimate?
      Bone Biologics Corp.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Bone Biologics Corp. have?
      Bone Biologics Corp. has 2,096,740 shares outstanding.
        What happened to Bone Biologics Corp.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Bone Biologics Corp.?
        Currently, no hedge funds are holding shares in BBLG
        ---

        Bone Biologics Stock Smart Score

        Company Description

        Bone Biologics Corp.

        Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
        ---
        Similar Stocks
        Company
        Price & Change
        Follow
        PAVmed
        Brainstorm Cell Therapeutics
        BioNano Genomics
        OncoCyte
        TFF Pharmaceuticals
        Popular Stocks
        ---
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis